CN100361995C - One-step preparation process of injection-grade sterile cefotaxime sodium - Google Patents

One-step preparation process of injection-grade sterile cefotaxime sodium Download PDF

Info

Publication number
CN100361995C
CN100361995C CNB2005101182351A CN200510118235A CN100361995C CN 100361995 C CN100361995 C CN 100361995C CN B2005101182351 A CNB2005101182351 A CN B2005101182351A CN 200510118235 A CN200510118235 A CN 200510118235A CN 100361995 C CN100361995 C CN 100361995C
Authority
CN
China
Prior art keywords
solvent
sodium
cefotaxime sodium
organic solvent
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2005101182351A
Other languages
Chinese (zh)
Other versions
CN1765901A (en
Inventor
赵玉山
王龙科
康恒军
黄文涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reyoung Pharmaceutical Co Ltd
Original Assignee
SHANDONG RUIYANG PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 200410155402 external-priority patent/CN1634932A/en
Application filed by SHANDONG RUIYANG PHARMACEUTICAL CO Ltd filed Critical SHANDONG RUIYANG PHARMACEUTICAL CO Ltd
Priority to CNB2005101182351A priority Critical patent/CN100361995C/en
Publication of CN1765901A publication Critical patent/CN1765901A/en
Application granted granted Critical
Publication of CN100361995C publication Critical patent/CN100361995C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

本发明涉及一种头孢噻肟钠的制备工艺,在溶媒中,由7-ACA和AE-活性酯在胺类中间反应物的作用下进行反应,加入苯并噻唑助溶剂,再加入钠成盐剂进行反应析出结晶而制得,其反应溶媒是由苯类有机溶剂、乙酸乙酯或丙酮与醇类有机溶剂组成的混合溶媒,将7-ACA与AE-活性酯搅拌,反应至澄清,然后加入苯并噻唑助溶剂,除菌过滤直接加入钠成盐剂进行成盐反应,待反应变混浊时,进行养晶处理,然后用头孢噻肟钠的不溶性有机溶剂把结晶析出,最后经过常规的结晶后处理得头孢噻肟钠成品。采用了混合溶媒,直接从7-ACA制备头孢噻肟钠,一步工艺操作,结晶情况好,生产周期短,劳动强度小,动力消耗少,生产成本低,还能提高产品收率,并且溶媒使用量降低,减少了溶媒对操作人员的危害,利于工业上实施应用。The invention relates to a preparation process of cefotaxime sodium. In a solvent, 7-ACA and AE-active ester are reacted under the action of amine intermediate reactants, benzothiazole co-solvent is added, and sodium is added to form a salt It is prepared by reacting and crystallizing with the agent. The reaction solvent is a mixed solvent composed of benzene organic solvent, ethyl acetate or acetone and alcohol organic solvent. Stir 7-ACA and AE-active ester, react until clear, and then Add benzothiazole co-solvent, sterilize and filter and directly add sodium salt-forming agent to carry out salt-forming reaction. When the reaction becomes turbid, carry out crystal growth treatment, and then use the insoluble organic solvent of cefotaxime sodium to separate the crystals, and finally undergo conventional After crystallization, the finished product of cefotaxime sodium can be obtained. Using a mixed solvent to prepare cefotaxime sodium directly from 7-ACA, one-step process operation, good crystallization, short production cycle, low labor intensity, low power consumption, low production cost, and can increase product yield, and the use of solvent The amount is reduced, which reduces the harm of the solvent to the operator, and is beneficial to the industrial application.

Description

注射级无菌头孢噻肟钠的一步法制备工艺 One-step preparation process of injection-grade sterile cefotaxime sodium

技术领域technical field

本发明涉及一种头孢噻肟钠的制备工艺,属于化合物的制备技术领域。The invention relates to a preparation process of cefotaxime sodium, which belongs to the technical field of compound preparation.

背景技术Background technique

头孢噻肟钠属于第三代头孢菌素的衍生物,广泛应用于治疗敏感细菌引起的的败血症、化脓性脑膜炎及呼吸道、泌尿道、胆道、骨和关节、皮肤和软组织、腹腔、消化道、五官、生殖器等部位的感染。现有的头孢噻肟钠制备工艺分两步操作,在二氯甲烷单一溶媒中,由7-ACA和AE-活性酯在胺类中间反应物的作用下进行反应,然后加入盐酸进行酸化,再降温析晶获取头孢噻肟;第二步再将头孢噻肟溶解,加入成盐剂进行成盐反应,用丙酮将结晶物析出。两步工艺操作,结晶情况不好,影响产品质量,溶媒使用量大,污染严重,劳动强度大,生产周期长,动力消耗大,生产成本高,产品收率低。Cefotaxime sodium is a third-generation cephalosporin derivative, widely used in the treatment of sepsis, suppurative meningitis and respiratory tract, urinary tract, biliary tract, bone and joint, skin and soft tissue, abdominal cavity and digestive tract caused by sensitive bacteria. , facial features, genitals and other parts of the infection. The existing cefotaxime sodium preparation process is divided into two steps. In a single solvent of dichloromethane, 7-ACA and AE-active ester react under the effect of amine intermediate reactant, then add hydrochloric acid to carry out acidification, and then Cool down and decrystallize to obtain cefotaxime; the second step is to dissolve cefotaxime, add a salt-forming agent to carry out a salt-forming reaction, and use acetone to precipitate crystals. Two-step process operation, poor crystallization, affects product quality, large solvent usage, serious pollution, high labor intensity, long production cycle, large power consumption, high production cost, and low product yield.

发明内容Contents of the invention

本发明的目的在于提供一种注射级无菌头孢噻肟钠的一步法制备工艺,溶媒使用量少,劳动强度小,生产周期短,生产成本低,产品收率高,质量好。The object of the present invention is to provide a one-step preparation process of injection-grade sterile cefotaxime sodium, which has less solvent usage, low labor intensity, short production cycle, low production cost, high product yield and good quality.

本发明所述的注射级无菌头孢噻肟钠的一步法制备工艺,在溶媒中,由7-ACA和AE-活性酯在胺类中间反应物的作用下进行反应,加入苯并噻唑助溶剂,再加入钠成盐剂进行反应析出结晶而制得,其反应溶媒是由苯类有机溶剂、乙酸乙酯或丙酮与醇类有机溶剂组成的混合溶媒,将7-ACA与AE-活性酯搅拌,反应至澄清,然后加入苯并噻唑助溶剂,除菌过滤直接加入钠成盐剂进行成盐反应,待反应变混浊时,进行养晶处理,然后用头孢噻肟钠的不溶性有机溶剂把结晶析出,最后经过常规的结晶后处理得头孢噻肟钠成品。The one-step preparation process of injection-grade sterile cefotaxime sodium of the present invention, in solvent, reacts by 7-ACA and AE-active ester under the effect of amine intermediate reactant, adds benzothiazole cosolvent , and then add sodium salt-forming agent to react and precipitate crystallization. The reaction solvent is a mixed solvent composed of benzene organic solvent, ethyl acetate or acetone and alcohol organic solvent. Stir 7-ACA and AE-active ester , react until clarified, then add benzothiazole co-solvent, sterilize and filter and directly add sodium salt-forming agent for salt-forming reaction, when the reaction becomes turbid, carry out crystal growth treatment, and then use the insoluble organic solvent of cefotaxime sodium to crystallize Precipitate, and finally obtain the finished product of cefotaxime sodium through conventional crystallization post-treatment.

反应方程式为:(见下页)The reaction equation is: (see next page)

Figure C20051011823500041
Figure C20051011823500041

本发明工艺由于采用了混合溶媒,可以不需要首先制作成头孢噻肟,再进行成盐反应制备头孢噻肟钠,而是直接从7-ACA制备头孢噻肟钠,一步工艺操作,简化了工艺过程,结晶情况好,生产周期短,缩短一半的时间,劳动强度小,动力消耗少,生产成本低,还能提高含量2%左右,收率达88%以上(以7-ACA计),并且溶媒使用量降低,仅为原来的75%,减少了溶媒对操作人员的危害。Because the process of the present invention adopts the mixed solvent, it is not necessary to make cefotaxime at first, and then carry out the salt-forming reaction to prepare cefotaxime sodium, but directly prepare cefotaxime sodium from 7-ACA, one-step process operation, which simplifies the process process, the crystallization situation is good, the production cycle is short, the time is shortened by half, the labor intensity is small, the power consumption is small, the production cost is low, and the content can be increased by about 2%, and the yield is more than 88% (calculated by 7-ACA), and The amount of solvent used is reduced to only 75% of the original, which reduces the harm of solvent to operators.

本发明中:In the present invention:

混合溶媒的组成体积比为:The composition volume ratio of mixed solvent is:

苯类有机溶剂、乙酸乙酯或丙酮∶醇类有机溶剂=1∶(1~0.5)。Benzene organic solvent, ethyl acetate or acetone:alcohol organic solvent=1:(1~0.5).

苯并噻唑助溶剂为二(三氯甲基)碳酸酯、氯代甲酸三氯甲酯、卤化氢或其它卤化物中的一种。The benzothiazole co-solvent is one of bis(trichloromethyl)carbonate, trichloromethyl chloroformate, hydrogen halide or other halides.

苯类有机溶剂为甲苯或二甲苯等。Benzene organic solvents are toluene or xylene and the like.

醇类有机溶剂为甲醇、乙醇或异丙醇等。Alcoholic organic solvents are methanol, ethanol or isopropanol and the like.

胺类中间反应物为三乙胺、二异丙胺或叔胺等。Amine intermediate reactant is triethylamine, diisopropylamine or tertiary amine etc.

成盐剂为异辛酸钠、醋酸钠(乙酸钠)、甲醇钠、碳酸钠等有机或无机钠盐中的一种,可以直接使用固体,也可以使用溶液。溶液由钠盐溶于或混合于混合溶媒中制成,使用相同的溶媒,处理方便。The salt-forming agent is one of organic or inorganic sodium salts such as sodium isooctanoate, sodium acetate (sodium acetate), sodium methylate, and sodium carbonate, and can be directly used as a solid or as a solution. The solution is prepared by dissolving or mixing sodium salt in a mixed solvent, and the same solvent is used for easy handling.

头孢噻肟钠的不溶性有机溶剂为甲苯、丙酮、乙酸乙酯、无水乙醇或异丙醇等,可择一或混合使用。The insoluble organic solvents of cefotaxime sodium are toluene, acetone, ethyl acetate, absolute ethanol or isopropanol, etc., which can be selected or used in combination.

成盐反应待反应溶液变混浊时,加入头孢噻肟钠粉做晶种再进行养晶处理,会改善结晶情况,提高结晶质量。Salt formation reaction When the reaction solution becomes turbid, adding cefotaxime sodium powder as a seed crystal and then carrying out crystal growth treatment will improve the crystallization situation and crystallization quality.

洗涤溶液可以使用乙酸乙酯和无水乙醇或二氯甲烷和甲醇的混合液,混合体积比可以为10∶(1~2)。The washing solution can be a mixture of ethyl acetate and absolute ethanol or dichloromethane and methanol, and the mixing volume ratio can be 10: (1-2).

使用钠盐作为成盐剂,析晶滤饼被洗涤后,最好再用体积比为3~5%水的丙酮溶液进行搅拌洗涤处理,保证产品质量。Using sodium salt as a salt-forming agent, after the crystallization filter cake is washed, it is better to use an acetone solution with a volume ratio of 3 to 5% of water for stirring and washing treatment to ensure product quality.

产品的生产要符合行业要求,并且其它未详细提及的工艺情况同常规操作,如反应物的配料情况符合反应方程要求、胺类中间反应物与7-ACA用量配比关系、苯并噻唑助溶剂及成盐剂的加入情况(助溶剂和成盐剂加入量为7-ACA投料量的0.5~2%)、反应温度4~10℃、养晶时间0.5~1小时、结晶的洗涤要求、干燥温度40~50℃、真空干燥的真空度控制为0.095~0.099MPa,等等。The production of the product must comply with the requirements of the industry, and other process conditions not mentioned in detail are the same as the conventional operation, such as the ingredients of the reactants meet the requirements of the reaction equation, the ratio of the amount of amine intermediate reactants to 7-ACA, the benzothiazole auxiliary The addition of solvent and salt-forming agent (the amount of co-solvent and salt-forming agent added is 0.5-2% of the 7-ACA feeding amount), the reaction temperature is 4-10°C, the crystal growth time is 0.5-1 hour, the crystallization washing requirements, The drying temperature is 40-50°C, the vacuum degree of vacuum drying is controlled at 0.095-0.099MPa, and so on.

本发明工艺采用了混合溶媒,直接从7-ACA制备头孢噻肟钠,一步工艺操作,简化了工艺过程,结晶情况好,生产周期短,劳动强度小,动力消耗少,生产成本低,还能提高产品收率,并且溶媒使用量降低,减少了溶媒对操作人员的危害,利于工业上实施应用。The process of the present invention adopts a mixed solvent to directly prepare cefotaxime sodium from 7-ACA. One-step process operation simplifies the process, good crystallization, short production cycle, low labor intensity, low power consumption, low production cost, and The product yield is improved, and the amount of solvent used is reduced, which reduces the harm of the solvent to operators, and is beneficial to industrial application.

具体实施方式Detailed ways

下面结合实施例对本发明作进一步说明。The present invention will be further described below in conjunction with embodiment.

实施例1Example 1

本发明所述的头孢噻肟钠的制备工艺如下:The preparation technology of cefotaxime sodium of the present invention is as follows:

向三颈瓶中加入120ml体积比为1∶1的甲苯与甲醇组成混合溶媒、20ml三乙胺,降温到5℃,加入20克7-ACA,28克AE-活性酯,保持5度反应60分钟,反应澄清后,加入3毫升浓盐酸,室温下加入异辛酸钠溶液成盐剂和0.1g亚硫酸氢钠抗氧剂,反应10分钟后再晶种养晶30分钟,然后再滴加甲苯150ml,滴加甲苯过程温度控制在20℃,2小时滴完,滴完后养晶30分钟放料,用50ml乙酸乙酯和5ml无水乙醇的混合液洗涤料饼,然后再将料饼加到140ml丙酮和6ml水的混合液中搅洗30分钟后放料,料饼再用少量丙酮洗涤料饼,湿品料在50℃、真空度为-0.097MPa的条件下干燥3小时即可。收干品头孢噻肟钠31克,产品收率为88%(以7-ACA计)。Add 120ml of toluene and methanol with a volume ratio of 1:1 to form a mixed solvent, 20ml of triethylamine, cool down to 5°C, add 20g of 7-ACA, 28g of AE-active ester, and keep at 5°C for 60 Minutes, after the reaction is clarified, add 3 milliliters of concentrated hydrochloric acid, add sodium isooctanoate solution salt forming agent and 0.1 g sodium bisulfite antioxidant at room temperature, react for 10 minutes, then seed and grow crystals for 30 minutes, and then add toluene dropwise 150ml, the temperature of the dropwise addition of toluene is controlled at 20°C, and the drop is completed in 2 hours. After the drop is completed, the crystal is grown for 30 minutes and the material is discharged. The mixture of 50ml ethyl acetate and 5ml absolute ethanol is used to wash the cake, and then add the cake Stir and wash in the mixture of 140ml acetone and 6ml water for 30 minutes, then discharge the material cake, wash the material cake with a small amount of acetone, and dry the wet product material for 3 hours at 50°C and a vacuum of -0.097MPa. Receive dry product cefotaxime sodium 31 grams, product yield is 88% (calculated as 7-ACA).

其中:成盐剂由13克异辛酸钠溶入15ml甲苯和15ml甲醇的混合液中制成。Wherein: the salt-forming agent is made by dissolving 13 grams of sodium isooctanoate into a mixed solution of 15 ml of toluene and 15 ml of methanol.

实施例2Example 2

向三颈瓶中加入120ml体积比为1∶1的甲苯与甲醇组成混合溶媒、20ml三乙胺,降温到7℃,加入20克7-ACA,28克AE-活性酯,保持7度反应63分钟,反应澄清后加入3ml浓盐酸,室温下加入成盐剂(13克异辛酸钠溶入15ml甲苯和15ml甲醇的混合液中制成),0.1g亚硫酸氢钠,再滴加甲苯至微浊时养晶30分钟,然后再滴加剩余的甲苯,滴加甲苯过程温度控制在22℃,共加入120ml,控制在1.5小时滴完,滴完后养晶30分钟放料,用50ml乙酸乙酯和5ml异丙醇的混合液洗涤料饼,然后再将料饼加到140ml丙酮和6ml水的混合液中搅洗20分钟后放料,料饼再用少量丙酮洗涤料饼,湿品料50度真空干燥3小时即可,收干品头孢噻肟钠31.2克.收率88.1%。Add 120ml of toluene and methanol with a volume ratio of 1:1 to form a mixed solvent, 20ml of triethylamine, cool down to 7°C, add 20g of 7-ACA, 28g of AE-active ester, and keep it at 7°C for 63 Minutes, add 3ml of concentrated hydrochloric acid after the reaction is clarified, add a salt-forming agent (13 grams of sodium isooctanoate dissolved in a mixture of 15ml of toluene and 15ml of methanol) at room temperature, 0.1g of sodium bisulfite, then add dropwise toluene to slightly When the crystal is cloudy, grow the crystal for 30 minutes, and then add the remaining toluene dropwise. The temperature of the dropwise addition of toluene is controlled at 22°C, a total of 120ml is added, and the drop is completed within 1.5 hours. Wash the cake with a mixture of ester and 5ml of isopropanol, then add the cake to a mixture of 140ml of acetone and 6ml of water, stir and wash for 20 minutes, then discharge the cake, then wash the cake with a small amount of acetone, wet material Vacuum drying at 50°C for 3 hours can yield 31.2 g of dry product cefotaxime sodium. The yield is 88.1%.

实施例3Example 3

向三颈瓶中加入120ml体积比为1∶0.8的甲苯与甲醇组成混合溶媒、20ml三乙胺,降温到4℃,加入20克7-ACA,28克AE-活性酯,保持5度反应65分钟,反应澄清后加入1g氯代甲酸三氯甲酯,室温下加入成盐剂(13克异辛酸钠溶入30ml混合溶媒中制成),0.1g亚硫酸氢钠,加晶种养晶30分钟,然后再滴加剩余的甲苯,滴加甲苯过程温度控制在18℃,共加入120ml,控制在1.8小时滴完,滴完后养晶30分钟放料,用50ml乙酸乙酯和5ml无水乙醇的混合液洗涤料饼,然后再将料饼加到150ml丙酮和6ml水的混合液中搅洗25分钟后放料,料饼再用少量丙酮洗涤料饼,湿品50度真空干燥即可。Add 120ml of toluene and methanol at a volume ratio of 1:0.8 to the three-neck flask to form a mixed solvent, 20ml of triethylamine, cool down to 4°C, add 20g of 7-ACA, 28g of AE-active ester, and keep at 5°C for 65 Minutes, add 1g of trichloromethyl chloroformate after the reaction is clarified, add a salt-forming agent (13 grams of sodium isooctanoate dissolved in 30ml of mixed solvent) at room temperature, 0.1g of sodium bisulfite, add crystal seeds to grow crystals for 30 minutes Minutes, then add the remaining toluene dropwise, the temperature of the dropwise addition of toluene is controlled at 18°C, a total of 120ml is added, and the drop is completed within 1.8 hours. Wash the cake with a mixture of ethanol, then add the cake to a mixture of 150ml acetone and 6ml water, stir and wash for 25 minutes, then discharge the cake, wash the cake with a small amount of acetone, and dry the wet product in vacuum at 50 degrees .

实施例4Example 4

向三颈瓶中加入120ml体积比为1∶0.5的甲苯与甲醇组成混合溶媒、20ml三乙胺,降温到6℃,加入20克7-ACA,28克AE-活性酯,保持5度反应55分钟,反应澄清后加入1g氯代甲酸三氯甲酯,室温下加入成盐剂(13克异辛酸钠溶入30ml混合溶媒中制成),0.1g亚硫酸氢钠,再滴加甲苯至微浊时养晶30分钟,然后再滴加剩余的甲苯,滴加甲苯过程温度控制在19℃,共加入120ml,控制在1.6小时滴完,滴完后养晶30分钟放料,用60ml丙酮和5ml异丙醇的混合液洗涤料饼,然后再将料饼加到150ml丙酮和6ml水的混合液中搅洗25分钟后放料,料饼再用少量丙酮洗涤料饼,湿品50度真空干燥3小时即可。Add 120ml of toluene and methanol at a volume ratio of 1:0.5 to the three-necked flask to form a mixed solvent, 20ml of triethylamine, cool down to 6°C, add 20g of 7-ACA, 28g of AE-active ester, and keep at 5°C for 55 Minutes, add 1g of trichloromethyl chloroformate after the reaction is clarified, add a salt-forming agent (13 grams of sodium isooctanoate dissolved in 30ml of mixed solvent) at room temperature, 0.1g of sodium bisulfite, then add dropwise toluene to slightly When the crystal is cloudy, grow the crystal for 30 minutes, and then add the remaining toluene dropwise. The temperature of the dropwise addition of toluene is controlled at 19°C, and a total of 120ml is added, and the drop is completed within 1.6 hours. Wash the cake with a mixture of 5ml of isopropanol, then add the cake to a mixture of 150ml of acetone and 6ml of water, stir and wash for 25 minutes, then discharge the cake, wash the cake with a small amount of acetone, and vacuum the wet product at 50 degrees Allow to dry for 3 hours.

实施例5Example 5

向三颈瓶中加入120ml体积比为1∶0.6的甲苯与甲醇组成混合溶媒、20ml三乙胺,降温到6.5℃,加入20克7-ACA,28克AE-活性酯,保持6.5度反应60分钟,反应澄清后加入1g二(三氯甲基)碳酸酯,室温下加入成盐剂10克异辛酸钠,0.1g亚硫酸氢钠,再滴加甲苯至微浊时养晶30分钟,然后再滴加剩余的甲苯,滴加甲苯过程温度控制在23℃,共加入120ml,控制在1.8小时滴完,滴完后养晶40分钟放料,用50ml丙酮和10ml无水乙醇的混合液洗涤料饼,然后再将料饼加到140ml丙酮和6ml水的混合液中搅洗30分钟后放料,料饼再用少量丙酮洗涤料饼,湿品料50度真空干燥3小时即可。Add 120ml of toluene and methanol at a volume ratio of 1:0.6 to the three-necked flask to form a mixed solvent, 20ml of triethylamine, cool down to 6.5°C, add 20g of 7-ACA, 28g of AE-active ester, and keep at 6.5°C for 60 Minutes, add 1g of bis(trichloromethyl)carbonate after the reaction is clarified, add 10 grams of sodium isooctanoate and 0.1 g of sodium bisulfite as a salt-forming agent at room temperature, then add toluene dropwise to grow crystals for 30 minutes when slightly turbid, and then Then add the remaining toluene dropwise. The temperature of the dropwise addition of toluene is controlled at 23°C. A total of 120ml is added, and the drop is completed within 1.8 hours. Material cake, then add material cake to the mixed solution of 140ml acetone and 6ml water and stir and wash for 30 minutes, then discharge the material cake, and then wash the material cake with a small amount of acetone, and vacuum dry the wet product material at 50 degrees for 3 hours.

实施例6~10Embodiment 6-10

将混合溶媒中的甲苯更换为二甲苯,其它情况分别同实施例1~5。The toluene in the mixed solvent is replaced by xylene, and other situations are respectively the same as in Examples 1-5.

实施例11~15Examples 11-15

将混合溶媒中的甲苯更换为乙酸乙酯,其它情况分别同实施例1~5。The toluene in the mixed solvent was replaced with ethyl acetate, and other conditions were respectively the same as in Examples 1-5.

实施例16~20Examples 16-20

将混合溶媒中的甲苯更换为丙酮,其它情况分别同实施例1~5。The toluene in the mixed solvent is replaced by acetone, and the other conditions are the same as in Examples 1-5 respectively.

实施例21~40Examples 21-40

将混合溶媒中的甲醇更换为乙醇,其它情况分别同实施例1~20。The methanol in the mixed solvent was replaced with ethanol, and other conditions were the same as in Examples 1-20.

实施例41~80Examples 41-80

将胺类中间反应物三乙胺更换为二异丙胺,其它情况分别同实施例1~40。The amine intermediate reactant triethylamine was replaced with diisopropylamine, and the other conditions were the same as in Examples 1-40.

选用不溶性有机溶剂为其中的两种或几种的任意比例混合进行试验,试验情况证明均可。Insoluble organic solvents are selected as two or more of them in any proportion to be mixed for the test, and the test results prove that it is acceptable.

Claims (7)

1.一种注射级无菌头孢噻肟钠的一步法制备工艺,在溶媒中,由7-ACA和AE-活性酯在三乙胺或二异丙胺胺类中间反应物的作用下进行反应,加入氯代甲酸三氯甲酯或氯化氢苯并噻唑助溶剂,再加入钠成盐剂进行反应析出结晶而制得,其特征在于反应溶媒是由苯类有机溶剂、乙酸乙酯或丙酮与醇类有机溶剂组成的混合溶媒,将7-ACA与AE-活性酯搅拌,反应至澄清,然后加入苯并噻唑助溶剂,除菌过滤直接加入钠成盐剂进行成盐反应,待反应变混浊时,进行养晶处理,然后用头孢噻肟钠的不溶性有机溶剂把结晶析出,最后经过常规的结晶后处理得头孢噻肟钠成品。1. A one-step preparation process of injection-grade sterile cefotaxime sodium, in solvent, reacts under the effect of triethylamine or diisopropylamine amine class intermediate reactant by 7-ACA and AE-active ester, It is prepared by adding trichloromethyl chloroformate or benzothiazole hydrogen chloride as a co-solvent, and then adding a sodium salt-forming agent for reaction and precipitation of crystallization. It is characterized in that the reaction solvent is made of benzene organic solvent, ethyl acetate or acetone and alcohols Mixed solvent composed of organic solvent, stir 7-ACA and AE-active ester, react until clear, then add benzothiazole co-solvent, sterilize and filter, directly add sodium salt-forming agent for salt-forming reaction, when the reaction becomes turbid, Carry out the crystal growth treatment, then use the insoluble organic solvent of cefotaxime sodium to separate out the crystals, and finally go through conventional crystallization post-processing to obtain the finished product of cefotaxime sodium. 2.根据权利要求1所述的注射级无菌头孢噻肟钠的一步法制备工艺,其特征在于混合溶媒的组成体积比为:苯类有机溶剂、乙酸乙酯或丙酮∶醇类有机溶剂=1∶(1~0.5)。2. the one-step preparation technique of injection-grade sterile cefotaxime sodium according to claim 1 is characterized in that the composition volume ratio of mixed solvent is: benzene organic solvent, ethyl acetate or acetone: alcohol organic solvent = 1: (1~0.5). 3.根据权利要求1或2所述的注射级无菌头孢噻肟钠的一步法制备工艺,其特征在于苯类有机溶剂为甲苯或二甲苯。3. according to claim 1 and the one-step preparation process of injection grade sterile cefotaxime sodium, it is characterized in that benzene organic solvent is toluene or dimethylbenzene. 4.根据权利要求1或2所述的注射级无菌头孢噻肟钠的一步法制备工艺,其特征在于醇类有机溶剂为甲醇或乙醇中的一种。4. according to claim 1 and the one-step preparation technique of injection grade sterile cefotaxime sodium, it is characterized in that the alcoholic organic solvent is a kind of in methyl alcohol or ethanol. 5.根据权利要求1所述的注射级无菌头孢噻肟钠的一步法制备工艺,其特征在于成盐剂为异辛酸钠溶液,由异辛酸钠溶于混合溶媒中制成。5. the one-step preparation process of injection-grade sterile cefotaxime sodium according to claim 1 is characterized in that the salt-forming agent is a sodium isooctanoate solution, which is dissolved in a mixed solvent and made by sodium isooctanoate. 6.根据权利要求1所述的注射级无菌头孢噻肟钠的一步法制备工艺,其特征在于头孢噻肟钠的不溶性有机溶剂为甲苯、二甲苯、丙酮、乙酸乙酯、无水乙醇或异丙醇中的一种或几种的混合。6. the one-step preparation technique of injection-grade sterile cefotaxime sodium according to claim 1 is characterized in that the insoluble organic solvent of cefotaxime sodium is toluene, xylene, acetone, ethyl acetate, dehydrated alcohol or One or a mixture of isopropanol. 7.根据权利要求6所述的注射级无菌头孢噻肟钠的一步法制备工艺,其特征在于析晶滤饼被洗涤后,再用体积比为3~5%水的丙酮溶液进行搅拌洗涤处理。7. the one-step preparation process of injection-grade sterile cefotaxime sodium according to claim 6 is characterized in that after the crystallization filter cake is washed, then the acetone solution with a volume ratio of 3 to 5% water is used for stirring and washing deal with.
CNB2005101182351A 2004-10-27 2005-10-21 One-step preparation process of injection-grade sterile cefotaxime sodium Expired - Fee Related CN100361995C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005101182351A CN100361995C (en) 2004-10-27 2005-10-21 One-step preparation process of injection-grade sterile cefotaxime sodium

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200410155402.5 2004-10-27
CN 200410155402 CN1634932A (en) 2004-10-27 2004-10-27 Process for preparing cefotaxime sodium
CNB2005101182351A CN100361995C (en) 2004-10-27 2005-10-21 One-step preparation process of injection-grade sterile cefotaxime sodium

Publications (2)

Publication Number Publication Date
CN1765901A CN1765901A (en) 2006-05-03
CN100361995C true CN100361995C (en) 2008-01-16

Family

ID=36742038

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005101182351A Expired - Fee Related CN100361995C (en) 2004-10-27 2005-10-21 One-step preparation process of injection-grade sterile cefotaxime sodium

Country Status (1)

Country Link
CN (1) CN100361995C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101613360B (en) * 2009-08-07 2011-04-27 哈药集团制药总厂 Method for preparing cefotaxime

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104840423A (en) * 2015-04-27 2015-08-19 四川制药制剂有限公司 Preparation process of cefotaxime sodium for injection
CN107049958A (en) * 2017-04-26 2017-08-18 四川制药制剂有限公司 The preparation technology of cefotaxime sodium for injection powder-injection
CN110283187A (en) * 2019-07-10 2019-09-27 辽宁美亚制药有限公司 A kind of preparation method promoting Cefotaxime Sodium product quality
CN111647006B (en) * 2020-04-25 2021-06-08 广东金城金素制药有限公司 Cefotaxime sodium pharmaceutical preparation and treatment of salmonella infection indications including typhoid fever and paratyphoid fever
CN113024580B (en) * 2021-03-10 2022-02-25 苏州东瑞制药有限公司 Preparation method of cefotaxime sodium

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224371A (en) * 1977-08-17 1980-09-23 Roussel Uclaf Sodium 3-acetoxylmethyl-7-[2-(2-amino-4-thiazolyl)-2-methoxyimino-acetamido]-ceph-3-eme-4-carboxylate
US5574154A (en) * 1994-09-29 1996-11-12 Alnejma Bulk Pharmaceutical Co. A.B.P.C. Process for the preparation of cephalosporanic compounds
CN1167112A (en) * 1996-05-01 1997-12-10 兰贝克赛实验室有限公司 Process for producing cephalosporin antibiotics
CN1394863A (en) * 2002-07-05 2003-02-05 上海新亚药业有限公司 Method for synthesizing cefotaxime sodium

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224371A (en) * 1977-08-17 1980-09-23 Roussel Uclaf Sodium 3-acetoxylmethyl-7-[2-(2-amino-4-thiazolyl)-2-methoxyimino-acetamido]-ceph-3-eme-4-carboxylate
US5574154A (en) * 1994-09-29 1996-11-12 Alnejma Bulk Pharmaceutical Co. A.B.P.C. Process for the preparation of cephalosporanic compounds
CN1167112A (en) * 1996-05-01 1997-12-10 兰贝克赛实验室有限公司 Process for producing cephalosporin antibiotics
CN1394863A (en) * 2002-07-05 2003-02-05 上海新亚药业有限公司 Method for synthesizing cefotaxime sodium

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101613360B (en) * 2009-08-07 2011-04-27 哈药集团制药总厂 Method for preparing cefotaxime

Also Published As

Publication number Publication date
CN1765901A (en) 2006-05-03

Similar Documents

Publication Publication Date Title
CN101607955B (en) Preparation method for low-residue lipoic acid
CN103539803B (en) A kind of method preparing ceftriaxone sodium
CN102286003B (en) Manufacture method of ceftazidime compound
AU2008321691B2 (en) Manufacturing method of 2-hydroxy-5-phenylalkylaminobenzoic acid derivatives and their salts
CN102351800A (en) Method for preparing 5-methylbenzimidazole-2-methyl carbamate
JP2021536497A (en) Manufacturing process of amantadine nitrate ester derivative
EP0001024A1 (en) Crystalline form of the sodium salt of an oxyimino derivative of the 7-aminothiazolylacetamido-cephalosporanic acid, process for its preparation and pharmaceutical compositions containing it
CN100335485C (en) One-step preparation process of aseptic ceftriaxone sodium for injection
CN1765901A (en) One-step preparation process of aseptic cefotaxime sodium for injection
CN101941980B (en) Crystallization purifying and precipitating method of piperacillin acid
CN114751846A (en) Preparation method of valine lipid salt of florfenicol
CN104341435B (en) The process for purification of ceftriaxone sodium
CN109810009B (en) An improved method for synthesizing L-thyroxine sodium
CN102199132A (en) Method for preparing 2-(2-amino-4-thiazole)-2(Z)-[[(tertbutyloxycarbonyl) methoxyl] imido] acetic acid and salt thereof
WO2020238779A1 (en) Method for synthesizing florfenicol
CN117756674A (en) A method for preparing FAI, a perovskite precursor material
WO2019037591A1 (en) Melphalan hydrochloride crystal form, preparation method therefor and application thereof
CN102391170B (en) A kind of preparation method of N, N-diallyl-5-methoxytryptamine hydrochlorides
CN105541813A (en) Imidazole acetonitrile derivative acid salt as well as preparation method and application thereof
CN101550144A (en) Preparation technique for mezlocillin
JP2007238596A (en) Direct process for forming amino acid dihydrochloride
CN1150203C (en) A kind of preparation method of clarithromycin
CN105198825B (en) A kind of preparation method of D seromycins
CN105384614B (en) A kind of synthetic method of trimethyl orthoacetate
CN102659713A (en) Preparation method for cefdinir side-chain acid active ester

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: RUIYANG PHARMACY CO., LTD.

Free format text: FORMER NAME OR ADDRESS: SHANGDONG RUIYANG PHARMACEUTICAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: No. 6 Erlang mountain road, Yiyuan County, Zibo, Shandong

Patentee after: REYOUNG PHARMACEUTICAL Co.,Ltd.

Address before: No. 6 Erlang mountain road, Yiyuan County, Zibo, Shandong

Patentee before: SHANDONG REYOUNG PHARMACEUTICA

PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: One-step preparation process of aseptic cefotaxime sodium for injection

Effective date of registration: 20161027

Granted publication date: 20080116

Pledgee: Agricultural Bank of China Limited by Share Ltd. Yiyuan county subbranch

Pledgor: REYOUNG PHARMACEUTICAL Co.,Ltd.

Registration number: 2016990000912

PLDC Enforcement, change and cancellation of contracts on pledge of patent right or utility model
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 256100 No. 6 Erlang Road, Yiyuan County, Zibo, Shandong

Patentee after: Ruiyang Pharmaceutical Co.,Ltd.

Address before: 256100 No. 6 Erlang Road, Yiyuan County, Zibo, Shandong

Patentee before: REYOUNG PHARMACEUTICAL Co.,Ltd.

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20201228

Granted publication date: 20080116

Pledgee: Agricultural Bank of China Limited by Share Ltd. Yiyuan county subbranch

Pledgor: REYOUNG PHARMACEUTICAL Co.,Ltd.

Registration number: 2016990000912

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080116